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Abstract
Aims Previous studies have shown that hypertrophic
cardiomyopathy mutation carriers have a decreased
myocardial energy efficiency, which is thought to play
a key role in the pathomechanism of hypertrophic car-
diomyopathy (HCM). The ENERGY trial aims to deter-
mine whether metabolic drugs correct decreased my-
ocardial energy efficiency in HCM mutation carriers
at an early disease stage.
Methods 40 genotype-positive, phenotype-nega-
tive MYH7 mutation carriers will be treated for two
months with trimetazidine or placebo in a double-
blind randomised study design. Directly before and
after treatment, study subjects will undergo an [11C]-
acetate positron emission tomography/computed
tomography (PET/CT) and cardiac magnetic reso-
nance (CMR) scan to measure myocardial energy
efficiency. Myocardial efficiency will be calculated as
the amount of oxygen the heart consumes to perform
work.
Conclusion The ENERGY trial will be the first proof of
concept study to determine whether metabolic drugs
are a potential preventive therapy for HCM. Given that
trimetazidine is already being used in clinical practice,
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there is large potential to swiftly implement this drug
in HCM therapy.
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Introduction
Background on hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most
common genetic cardiomyopathy with an estimated
prevalence of 1:500 to 1:200 [1–4]. It is a cause of
acute cardiac arrest at a young age and cardiac trans-
plantation in end-stage heart failure patients [1, 2]. As
familial HCM is an autosomal dominant genetic disor-
der, most patients are heterozygous for the mutation
and carry one mutant and one normal allele. Even
though the gene mutation is present at birth, disease
onset generally occurs between 20 and 50 years of
age, thus affecting patients in the prime of their life.
The sarcomeric gene mutation causing HCM was first
identified more than 25 years ago. Currently >1,400
HCM mutations have been found, of which ~90%
reside in the genes encoding thick and thin filament
proteins of the sarcomere [4]. The 3 most frequently
affected genes (MYH7, MYBPC3 and TNNT2) encode
the sarcomeric proteins myosin heavy chain (MyHC),
myosin-binding protein C (cMyBP-C) and troponin T
(cTnT) [2, 4]. With the advance in genetic screening,
more genotype-positive phenotype-negative (G+/Ph-)
individuals are currently being identified, which in-
creases the number of people that are insecure of
their fate as treatment to prevent disease is lacking
[5].
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Fig. 1 The ratio between external work and myocardial oxy-
gen consumption to obtain myocardial external efficiency
was determined in 28 asymptomatic mutation carriers (14
MYBPC3 and 14 MYH7), 10 manifest HCM patients and 14
healthy controls using [11C]-acetate positron emission tomog-
raphy (PET) and cardiovascular magnetic resonance imaging
(CMR). a CMR-derived cardiac 4-chamber view and paramet-
ric images of [11C]-acetate PET derived k2 with corresponding
polar maps. As can be seen clearly, oxygen metabolism was
higher in asymptomatic mutation carriers compared to con-
trols [7]. b Myocardial efficiency is not further reduced in
advanced HCM patients compared with mutation carriers [8]
Inefficient cardiac pump function as target for
therapy: proof from preclinical and clinical studies
Using metabolic therapy we aim to reverse deficits
in cardiac energetics, which are observed at the very
early disease stage in seemingly healthy (asymp-
tomatic) mutation carriers (Fig. 1). A reduced ratio
between phosphocreatine and adenosine triphos-
phate (PCr/ATP), a measure of energetic status of
the heart, was observed in mutation carriers without
hypertrophy [6]. In addition, myocardial external ef-
ficiency was significantly reduced in asymptomatic
individuals with mutations in genes encoding thick
filament proteins [7]. Imaging studies in HCM pa-
tients with advanced disease showed that myocar-
dial efficiency did not further decline compared to
asymptomatic mutation carriers, indicating that en-
ergy deficiency is an early change in the heart before
the development of hypertrophy [8]. Research data
has suggested that at cardiac muscle cell level, two
mutation-mediated changes in myofilament function
underlie reduced cardiac efficiency in HCM. Firstly,
the mutation-induced increase in ATP utilisation of
sarcomeres, which was reported in transgenic HCM
mice [9]. In line with these findings, our studies in car-
diac tissue from HCM patients showed an increased
cost of muscle contraction, illustrated by a~ 2-fold
higher tension cost (ratio between ATP utilisation
and generated force) compared with controls [7, 10].
Secondly, a mutation-related increase in myofilament
calcium sensitivity was found in HCM mouse models
[11], which increases both force development and
ATP consumption. In accordance with HCM mouse
models, studies in human cardiac tissue revealed
higher calcium sensitivity in HCM human cardiac
tissue compared with controls [12, 13]. Overall, these
studies show that inefficient cardiac pump function
and altered energetic status occur at an early disease
stage even before development of cardiac hypertro-
phy, and may thus represent a target for preventive
therapy.
Metabolic therapy as potential preventive therapy in
HCM
Metabolic agents, which are already used in clinical
practice such as anti-anginal agents, may be used to
improve cardiac energetics and function [14–19]. In
the healthy heart energy demand is met by oxidation
of fatty acids and carbohydrates. Although fatty acids
represent the predominant fuel for the heart, they pro-
vide less ATP per O2 molecule in comparison to car-
bohydrates [14]. Thus, agents which shift metabolism
away from the preferred fatty acids towards carbo-
hydrates would increase ATP supply and may pre-
vent cardiac hypertrophy and failure. Abozguia et al.
showed that metabolic therapy with perhexiline had
a beneficial effect in advanced HCM [20]. We recently
demonstrated that myocardial efficiency is already re-
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Fig. 2 ENERGY trial study
design  PET/CT, CMR, cardiac echo
 ECG & exercise test
 Fasting blood tests
Consenting 
asymptomatic 
MYH7 mutation 
carriers (n=40)
 PET/CT, CMR, cardiac echo
 ECG & exercise test
 Fasting blood tests
 Clinical check-up by research
nurse after 1 month
 Trimetazidine plasma assay
Allocated to 
trimetazidine
n=20
Trimetazidine 
group 2 months 
follow-up
Placebo group 
2 months
follow-up
Allocated to 
placebo
n=20
duced in healthy human mutation carriers [7, 10].
Therefore, optimising the energetic status of the heart
may benefit mutation carriers at a very early disease
stage before hypertrophy is evident. The ENERGY trial
will be a proof of concept study which builds on these
previous preclinical and clinical studies. We aim to
determine whether metabolic therapy has the poten-
tial to restore the reduced cardiac efficiency in HCM
mutation carriers.
Metabolic therapy with trimetazidine
Trimetazidine is an anti-anginal drug, indicated as
add-on therapy for the symptomatic treatment of sta-
ble angina pectoris in adults who are inadequately
controlled by first-line therapies. Trimetazidine in-
hibits β-oxidation of fatty acids by blocking the mito-
chondrial long-chain 3-ketoacyl coenzyme A thiolase
enzyme in the mitochondria [21]. Consequently, glu-
cose oxidation is stimulated which yields more ATP
per molecule O2, resulting in a more oxygen-efficient
metabolism. The improved energy efficiency ob-
tained with trimetazidine has the potential to correct
the energy deficiency observed in HCM. As both ex
vivo and in vivo studies showed a more severe energy
deficiency in MYH7 compared with MYBPC3 muta-
tions, we will include asymptomatic MYH7 mutation
carriers in the ENERGY trial. This clinical trial will
be a proof of concept study to determine whether
trimetazidine can improve the myocardial energy ef-
ficiency of asymptomatic MYH7 mutation carriers, as
measured by [11C]-acetate positron emission tomog-
raphy/computed tomography (PET/CT) and cardiac
magnetic resonance (CMR) scans.
Study design
The ENERGY trial is a randomised, double-blind,
placebo-controlled trial. A flow chart of the trial can
be found in Fig. 2. Randomisation will be done by
randomised block randomisation stratified for the
participants’ sex.
Methods
Ethics
This study will be conducted in accordance with the
guidelines for Good Clinical Practice. The study will
be performed in accordance with the Declaration
of Helsinki (64th WMA General Assembly, Fortaleza,
Brazil, October 2013). The study has been approved
by the Medical Ethical Testing Committee of the VU
medical centre.
Myocardial efficiency
Myocardial efficiency is the amount of oxygen the
heart consumes to perform work. [11C]-acetate
PET/CT imaging will be used to indirectly quan-
tify myocardial oxygen consumption (MVO2). CMR
will be performed to calculate cardiac mechanical
external work (EW), which is the product of stroke
volume and mean arterial pressure. With MVO2 and
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EW, myocardial efficiency can be calculated using the
following equation:
MEE = EW ·HR ·1.33×10
−4
MVO2 ·LV M ·20
MEE myocardial energy efficiency
HR heart rate
LVM left ventricular mass
Study objectives
Primary objective Tomeasure the effect of trimetazi-
dine on myocardial external efficiency in asymp-
tomatic MYH7 mutation carriers.
Secondary objectives To study the effect of trimetazi-
dine in asymptomatic MYH7 mutation carriers on:
 cardiac diastolic function, as measured by echocar-
diography
 volume parameters of the left ventricle of the heart,
measured by CMR.
 exercise capacity: duration of exercise and per-
formed workload
 electrophysiological properties of the heart, mea-
sured by ECG
Study population
Potential study subjects will be recruited in the HCM
outpatient clinic in the Erasmus Medical Center Rot-
terdam. Asymptomatic carriers of a class 5 MYH7
mutation (definite disease causing mutations) will be
asked to participate by their clinician. Recruitment
will start in January 2019 until 40 study subjects have
been included in the study. After written consent is
obtained, participants will be screened for inclusion
and exclusion criteria and will be included in the study
if they meet the requirements.
Inclusion criteria In order to be eligible to partici-
pate in this study, a subject must meet all of the fol-
lowing criteria:
 18–65 years old
 Class 5 MYH7 mutation identified by pre-symp-
tomatic genetic screening
Exclusion criteria A potential subject who meets
any of the following criteria will be excluded from
participation in this study:
 Cardiovascular disease
 Hypertrophic cardiomyopathy (maximal wall thick-
ness≥ 15mm)
 Wall motion disorders
 Diabetes mellitus
 Any absolute or relative contra-indication for mag-
netic resonance imaging (MRI) (i. e. metallic im-
plants and claustrophobia)
 Inability to give informed consent.
 Severely impaired renal function with a glomerular
filtration rate (GFR)< 30ml/min
 Parkinson’s disease and related symptoms
Sample size calculation
The high sensitivity of the methodology enables to
study effects of therapy in a relatively small study
group. To reveal a 15% beneficial effect of trimetazi-
dine on myocardial energy efficiency, taking into ac-
count a standard deviation of 15% based on our pre-
vious studies of myocardial energy efficiency in HCM
mutation carriers [7], a number of 20 carriers should
be included in each group (with metabolic therapy or
placebo) to reach a power of 80% (significance level
0.05).
Statistical analysis
Primary and secondary study parameters are all quan-
titative, continuous variables. Variables will be sum-
marised by means and standard deviation or median
and interquartile range, depending on whether they
or normally distributed or not. Normality will be as-
sessed using normal probability plots. The primary
analysis will be based on intention-to-treat. Missing
data will not be imputed. We will use methods, such
as mixed model analyses, that are valid under the as-
sumption that data is missing at random. Results will
be considered statistically significant with a two-tailed
p-value< 0.05.
The primary study parameter will be analysed with
an ANCOVA analysis. A linear regression model will
be used with measurements on day 61 as the depen-
dent variable and treatment group (trimetazidine or
placebo group) and the baseline (day 0) measurement
as independent variables. The secondary study pa-
rameters will be analysed in a mixed model analysis.
The models will include treatment group, time point,
and interaction as fixed independent variables. The
models will also include a random effect for subject.
Discussion
The ENERGY trial will be the first proof of concept
study to determine whether metabolic drugs correct
decreased myocardial energy efficiency in asymp-
tomatic mutation carriers at an early disease stage.
After giving informed consent, 40 asymptomatic, pre-
hypertrophic MYH7 mutation carriers will be treated
for two months with trimetazidine or placebo. Di-
rectly before and after treatment, study subjects will
undergo an [11C]-acetate PET/CT and CMR scan to
measure myocardial energy efficiency. A positive re-
sult of this trial will help to build proof that metabolic
therapy has the potential to become a preventive
therapy for HCM. Given that trimetazidine is already
used in clinical practice, there is large potential to
swiftly implement this drug in HCM therapy.
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Trimetazidine is an anti-anginal drug that does not
alter the haemodynamic state of the body. Its car-
dioprotective effect is not yet fully understood, but
has been suggested to improve the metabolic state
of the heart through a number of mechanisms, such
as improvement of energy efficiency by inhibition of
free fatty acid β-oxidation, inhibition of fibrosis, and
reduction of oxidative stress, calcium overload and
acidosis in the cardiomyocyte [15, 22–24]. Side ef-
fects of trimetazidine are mostly mild and well tol-
erated, with nausea, vomiting and minor headaches
being most common. However, in 2011 the European
Medicines Agency (EMA) initiated a safety assessment
of trimetazidine after a study with trimetazidine re-
ported Parkinson’s disease and related symptoms in
43% of patients [25]. A cumulative review was per-
formed for all spontaneous adverse drug reactions
from 1964 to 2011, which estimated the occurrence
of this side effect to be 0.36/100,000 patient-years,
and reversible in almost 80% of cases [26]. The EMA
concluded that the benefits of trimetazidine outweigh
the risks in patients with angina pectoris, but that
trimetazidine is no longer authorized in the treatment
of tinnitus, vertigo or visual field disturbances. Fur-
thermore, use of trimetazidine should be contra-indi-
cated in patients with Parkinson’s disease and other
related movement disorders, and in patients with se-
vere renal impairment (GFR<30ml/min) [26].
Advancements in genetic screening have led to the
identification of a group of individuals, the G+/Ph-
group, at risk for developing HCM. This has paved
the way for research into therapeutic strategies such
as metabolic therapy to prevent the development
of HCM in those at risk. New therapeutic strate-
gies emerge as new aspects of HCM pathophysiology
are discovered. However, it is unclear whether the
different mutations that cause HCM have the same
pathomechanism, or that each mutation has its own
distinct pathway to disease. This is especially rele-
vant for potential therapeutic strategies, which might
only work in patients with a specific mutation. Clin-
ical trials might lead to disappointing results when
patients with different HCM mutations are pooled
into the same treatment category. For this reason,
the ENERGY trial will only include MYH7 mutation
carriers, based on previous research which showed
that MYH7 mutation carriers have the most severe de-
crease in myocardial energy efficiency [7]. Moreover,
it is still unknown why some individuals in the G+/Ph-
group never develop HCM, while others develop the
disease early in life. If trimetazidine has the poten-
tial to become a preventive therapy, development of
strategies to accurately identify those at high risk of
developing HCM will be crucial to determine who will
benefit from preventive therapy.
Funding We acknowledge funding from ZonMW and Heart
Foundation for the translational research program, project
95105003.
Conflict of interest B.O. van Driel, A.C. van Rossum, M. Mi-
chels, R. Huurman and J. van der Velden declare that they
have no competing interests.
Open Access This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which per-
mits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the origi-
nal author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
References
1. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC
guidelines on diagnosis andmanagement of hypertrophic
cardiomyopathy: theTaskForcefortheDiagnosisandMan-
agementofHypertrophicCardiomyopathyoftheEuropean
SocietyofCardiology(ESC).EurHeartJ.2014;35:2733–79.
2. Watkins H, Ashrafian H, Redwood C. Inherited cardiomy-
opathies. NEngl JMed. 2011;364:1643–56.
3. Semsarian C, Ingles J, MaronMS, Maron BJ. New perspec-
tives on the prevalence of hypertrophic cardiomyopathy.
JAmCollCardiol. 2015;65:1249–54.
4. Ho CY, Charron P, Richard P, Girolami F, Van Spaen-
donck-Zwarts KY, Pinto Y. Genetic advances in sarcom-
eric cardiomyopathies: state of the art. Cardiovasc Res.
2015;105:397–408.
5. van der Velden J, Ho CY, Tardiff J, Olivotto I, Knollmann
BC, Carrier L. Research priorities in sarcomeric cardiomy-
opathies. CardiovascRes. 2015;105:449–56.
6. Crilley JG,BoehmEA,BlairE,etal. Hypertrophiccardiomy-
opathy due to sarcomeric genemutations is characterized
byimpairedenergymetabolismirrespectiveofthedegreeof
hypertrophy. JAmCollCardiol. 2003;41:1776–82.
7. Witjas-Paalberends ER, Güçlü A, Germans T, et al. Gene-
specific increase in energetic cost of contraction in hyper-
trophic cardiomyopathy caused by thick filament muta-
tions. CardiovascRes. 2014;103:248–57.
8. Güçlü A, Knaapen P, Harms HJ, et al. Disease stage-
dependentchangesincardiaccontractileperformanceand
oxygen utilization underlie reduced myocardial efficiency
in human inherited hypertrophic Cardiomyopathy. Circ
CardiovascImaging. 2017;10:e5604.
9. ChandraM,TschirgiML,Tardiff JC. Increase in tension-de-
pendent ATP consumption induced by cardiac troponin T
mutation. AmJPhysiolHeartCircPhysiol. 2005;289:2112–9.
10. Witjas-Paalberends ER, Ferrara C, Scellini B, et al. Faster
cross-bridgedetachmentand increased tensioncost inhu-
man hypertrophic cardiomyopathy with the R403QMYH7
mutation. JPhysiol. 2014;592:3257–72.
11. Schober T, Huke S, Venkataraman R, et al. Myofilament Ca
sensitization increases cytosolic Ca binding affinity, alters
intracellularCahomeostasis, andcausespause-dependent
Ca-triggeredarrhythmia. CircRes. 2012;111:170–9.
12. SequeiraV,WijnkerPJM,NijenkampLLAM,etal. Perturbed
length-dependent activation in human hypertrophic car-
diomyopathy with missense sarcomeric gene mutations.
CircRes. 2013;112:1491–505.
13. Lan F, Lee AS, Liang P, et al. Abnormal calcium handling
properties underlie familial hypertrophic cardiomyopathy
pathology in patient-specific induced pluripotent stem
cells. CellStemCell. 2013;12:101–13.
14. Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid
oxidationinheartfailure. CardiovascRes. 2011;90:202–9.
204 Extra energy for hearts with a genetic defect: ENERGY trial
Original Article – Design Study Article
15. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antiang-
inal drug trimetazidine shifts cardiac energy metabolism
fromfatty acid oxidation to glucose oxidationby inhibiting
mitochondrial long-chain3-ketoacyl coenzymeA thiolase.
CircRes. 2000;86:580–8.
16. Mody FV, Singh BN, Mohiuddin IH, et al. Trimetazidine-
induced enhancement ofmyocardial glucoseutilization in
normal and ischemic myocardial tissue: an evaluation by
positronemissiontomography. AmJCardiol. 1998;82:42–9.
17. BelardinelliR,PurcaroA.Effectsoftrimetazidineonthecon-
tractile responseof chronically dysfunctionalmyocardium
to low-dose dobutamine in ischemic cardiomyopathy. Eur
HeartJ.2001;22:2164–70.
18. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial sub-
stratemetabolism in the normal and failing heart. Physiol
Rev. 2005;85:1093–129.
19. LeeL,Horowitz J, FrenneauxM.Metabolicmanipulation in
ischaemicheartdisease,anovelapproachtotreatment. Eur
HeartJ.2004;25:634–41.
20. Abozguia K, Elliott P, McKenna W, et al. Metabolic modu-
lator perhexiline corrects energy deficiency and improves
exercise capacity in symptomatic hypertrophic cardiomy-
opathy. Circulation. 2010;122:1562–9.
21. Dézsi CA. Trimetazidine in practice: review of the clinical
andexperimentalevidence. AmJTher. 2016;23:871–9.
22. Iskesen I, Saribulbul O, Cerrahoglu M, Var A, Nazli Y, Sirin
H.Trimetazidinereducesoxidativestressincardiacsurgery.
CircJ.2006;70:1169–73.
23. Marzilli M. Cardioprotective effects of trimetazidine: a re-
view. CurrMedResOpin. 2003;19:661–72.
24. LiuX,GaiY,LiuF,etal. Trimetazidineinhibitspressureover-
load-induced cardiac fibrosis through NADPH oxidase-
ROS-CTGFpathway. CardiovascRes. 2010;88:150–8.
25. Masso MJF, Marti I, Carrera N, Poza JJ, Lopez de Munain
A. Trimetazidine induces parkinsonism, gait disorders and
tremor. Therapie. 2005;60:419–22.
26. European Medicines Agency. Science Medicines Health.
European Medicines Agency recommends restricting use
of trimetazidine-containingmedicines. Press release. Eu-
ropeanMedicinesAgency. EMA/CHMP/417861/2012. Eu-
ropean Medicines Agency: European Medicines Agency;
2012.
Extra energy for hearts with a genetic defect: ENERGY trial 205
